P131 Efficacy of tiotropium and olodaterol combination in patients with COPD on β-blockers. (12th November 2015)

• Record Type: Journal Article
• Authors: Derom, E; Korn, S; Hamilton, A; Amatto, VC; Zhao, Y; Maltais, F
• Is Part Of: Thorax. Volume 70(2015)Supplement 3
• Page Start: A142
• Page End: A142
• Publication Date: 2015-11-12
• Subjects: Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thoraxjnl-2015-207770.268
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Rationale: The efficacy and safety of a new once-daily combination with tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β2 -agonist, was established for the treatment of chronic obstructive pulmonary disease (COPD) in the TONADO studies (NCT01431274 ; NCT01431287 ). This analysis evaluates the efficacy of the combination in a subpopulation of patients receiving β-blockers in these studies. Methods: Two replicate, randomised, double-blind, parallel-group, 52-week, Phase III trials assessed the efficacy and safety of T+O (2.5/5 μg; 5/5 μg; via Respimat® inhaler) once daily compared to the monocomponents. Key primary end-point data for the combined analysis of the replicate trials in patients with COPD receiving β-blockers during treatment are presented. Results: 5136 patients were evaluable; 556 (10.8%) received β-blockers. At 24 weeks, similar improvements in mean forced expiratory volume in 1 s (FEV1 ) area under the curve from 0–3 h (AUC0–3 ) responses for T+O compared to monocomponents were seen across β-blocker subgroups (Table 1 ), with no significant treatment interaction effect observed. A similar trend was observed with trough FEV1 and quality of life scores. Conclusions: While the β-blocker patient group analysed was small, these data demonstrated similar sustained improvements in lung function, irrespective of β-blocker use. These data support the efficacy of T+O in this patient group. Funding: Boehringer Ingelheim.